GlassScriptPhysician profile
Massarat A Bala
NPI 1730196833
$17,995.90
in general payments reported to CMS, 2019-2025
53 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,013 · 2020: $2,758 · 2021: $3,559 · 2022: $2,983 · 2023: $2,005 · 2024: $2,170 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,682.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,779.16 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Abbvie INC. | $1,767.55 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,547.52 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $1,449.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,411.22 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $1,213.68 | 2019-2025 | |
| Dexcom, INC. | $1,128.12 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $1,041.01 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $821.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $753.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $601.91 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $567.65 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $461.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $344.61 | 2021-2023 | |
| Amgen INC. | $304.90 | 2020-2025 | Krystexxa, Repatha, Otezla |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massarat Bala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.